Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia

Alexanian, R. , Weber, D. , Delasalle, K. , Cabanillas, F. & Dimopoulos, M. (2003) Asymptomatic Waldenstrom’s macroglobulinemia. Seminars in Oncology, 30, 206–210. Baldini, L. , Goldaniga, M. , Guffanti, A. , Broglia, C. , Cortelazzo, S. , Rossi, A. , Morra, E. , Colombi, M. , Callea, V. , Pogliani, E. , Ilariucci, F. , Luminari, S. , Morel, P., Merlini, G. & Gobbi, P. (2005) Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom’s macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. Journal of Clinical Oncology, 23, 4662–4668. Boffa, D.J., Rosen, J.E. , Mallin, K. , Loomis, A. , Gay, G. , Palis, B. , Thoburn, K. , Gress, D. , McKellar, D.P., Shulman, L.N. , Facktor, M.A. & Winchester, D.P. (2017) Using the National cancer database for outcomes research: a review. JAMA Oncology, 3, 1722–1728. https://doi.org/ 10.1001/jamaoncol.2016. 6905 Castillo, J.J., Olszewski, A.J., Cronin, A.M., Hunter, Z.R. & Treon, S.P. (2014) Survival trends in Waldenstrom macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood, 123, 3999–4000. Gobbi, P.G. , Baldini, L. , Broglia, C. , Goldaniga, M. , Comelli, M. , Morel, P., Morra, E. , Cortelazzo, S. , Bettini, R. & Merlini, G. (2005) Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Clinical Cancer Research, 11, 1786–1790. Greco, A. , Tedeschi, A. , Varettoni, M. , Nichelatti, M. , Paris, L. , Ricci, F. , Vismara, E. & Morra, E. (2011) Factors predicting transformation of asymptomatic IgM monoclonal gammopathy. Clinical Lymphoma, Myeloma & Leukemia, 11, 77–79. Kapoor, P., Ansell, S.M. , Fonseca, R. , ChananKhan, A. , Kyle, R.A. , Kumar, S.K. , Mikhael, J.R. , Witzig, T.E. , Mauermann, M. , Dispenzieri, A. , Ailawadhi, S. , Stewart, A.K. , Lacy, M.Q. , Thompson, C.A. , Buadi, F.K. , Dingli, D. , Morice, W.G. , Go, R.S. , Jevremovic, D. , Sher, T. , King, R.L. , Braggio, E. , Novak, A. , Roy, V. , Ketterling, R.P., Greipp, P.T. , Grogan, M. , Micallef, I.N. , Bergsagel, P.L. , Colgan, J.P., Leung, N. , Gonsalves, W.I. , Lin, Y. , Inwards, D.J., Hayman, S.R. , Nowakowski, G.S. , Johnston, P.B. , Russell, S.J., Markovic, S.N. , Zeldenrust, S.R. , Hwa, Y.L. , Lust, J.A. , Porrata, L.F. , Habermann, T.M. , Rajkumar, S.V. , Gertz, M.A. & Reeder, C.B. (2017) Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol, 3, 1257–1265. Kyle, R.A. , Benson, J., Larson, D. , Therneau, T. , Dispenzieri, A. , Melton Iii, L.J. & Rajkumar, S.V. (2009) IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstrom’s macroglobulinemia. Clinical Lymphoma & Myeloma, 9, 17–18. Kyle, R.A. , Benson, J.T. , Larson, D.R. , Therneau, T.M. , Dispenzieri, A. , Kumar, S. , Melton, L.J. 3rd & Rajkumar, S.V. (2012) Progression in smouldering Waldenstrom macroglobulinemia: long-term results. Blood, 119, 4462–4466. Ravindran, A. , Bartley, A.C. , Holton, S.J., Gonsalves, W.I. , Kapoor, P., Siddiqui, M.A., Hashmi, S.K. , Marshall, A.L. , Ashrani, A.A. , Dispenzieri, A. , Kyle, R.A. , Rajkumar, S.V. & Go, R.S. (2016) Prevalence, incidence and survival of smouldering multiple myeloma in the United States. Blood Cancer Journal, 6, e486.